NCT04497948View on ClinicalTrials.gov

Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19

PHASE1TerminatedINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

September 21, 2020

Primary Completion Date

November 18, 2020

Study Completion Date

November 18, 2020

Conditions

COVID-19

Interventions

DRUG

Acalabrutinib

Acalabrutinib (CALQUENCE®) is a covalent BTK inhibitor

Trial Locations (4)

90035-003

Research Site, Porto Alegre

14051-140

Research Site, Ribeirão Preto

01321-001

Research Site, São Paulo

01323-903

Research Site, São Paulo

Sponsors

Lead Sponsor

Acerta Pharma BV

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

Acerta Pharma BV

INDUSTRY